Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1953 1
1955 1
1956 1
1960 8
1961 16
1962 21
1963 24
1964 26
1965 20
1966 11
1967 19
1968 16
1969 14
1970 9
1971 18
1972 16
1973 5
1974 10
1975 10
1976 8
1977 9
1978 13
1979 4
1980 3
1981 8
1982 3
1983 7
1984 4
1985 5
1986 9
1987 6
1988 5
1989 3
1990 8
1991 11
1992 3
1993 6
1994 8
1995 3
1996 8
1997 4
1998 5
1999 8
2000 25
2001 49
2002 71
2003 77
2004 100
2005 103
2006 135
2007 120
2008 121
2009 107
2010 119
2011 122
2012 96
2013 112
2014 114
2015 102
2016 99
2017 98
2018 100
2019 108
2020 125
2021 138
2022 133
2023 136
2024 60

Text availability

Article attribute

Article type

Publication date

Search Results

2,704 results

Results by year

Filters applied: . Clear all
Page 1
Galantamine beyond Alzheimer's disease-a fact or artefact?
Naguy A, Husain K, Alamiri B. Naguy A, et al. CNS Spectr. 2022 Jun;27(3):268-271. doi: 10.1017/S1092852920002229. Epub 2020 Dec 14. CNS Spectr. 2022. PMID: 33308343 Review.
Galantamine is US-Food and Drug Administration FDA-approved for mild-to-moderate Alzheimer's disease. ...
Galantamine is US-Food and Drug Administration FDA-approved for mild-to-moderate Alzheimer's disease. ...
Galantamine in Alzheimer's disease.
Razay G, Wilcock GK. Razay G, et al. Expert Rev Neurother. 2008 Jan;8(1):9-17. doi: 10.1586/14737175.8.1.9. Expert Rev Neurother. 2008. PMID: 18088197 Review.
Galantamine is a cholinesterase inhibitor with a dual mechanism of action. ...The magnitude of the treatment effect is similar to that of other cholinesterase inhibitors. Adverse events experienced by patients treated with galantamine are usually mild, gastrointesti …
Galantamine is a cholinesterase inhibitor with a dual mechanism of action. ...The magnitude of the treatment effect is similar to tha …
Galantamine-ER for the treatment of mild-to-moderate Alzheimer's disease.
Seltzer B. Seltzer B. Clin Interv Aging. 2010 Feb 2;5:1-6. Clin Interv Aging. 2010. PMID: 20169037 Free PMC article. Review.
Except for predicted differences in (C(max)) and t(max), comparable doses of once daily galantamine-ER and regular, immediate release galantamine, (galantamine-IR), are pharmacologically equivalent. ...There was no difference in drug-related adverse events be …
Except for predicted differences in (C(max)) and t(max), comparable doses of once daily galantamine-ER and regular, immediate release …
Galantamine for Alzheimer's disease.
Prvulovic D, Hampel H, Pantel J. Prvulovic D, et al. Expert Opin Drug Metab Toxicol. 2010 Mar;6(3):345-54. doi: 10.1517/17425251003592137. Expert Opin Drug Metab Toxicol. 2010. PMID: 20113148 Review.
AREAS COVERED IN THIS REVIEW: Here, we review a body of placebo-controlled studies as well as meta-analyses on the cholinesterase (ChE) inhibitor galantamine, one of only four drugs currently approved for anti-dementia therapy in AD. ...As long as no other drug therapies w …
AREAS COVERED IN THIS REVIEW: Here, we review a body of placebo-controlled studies as well as meta-analyses on the cholinesterase (ChE) inhi …
Galantamine for Alzheimer's disease.
Loy C, Schneider L. Loy C, et al. Cochrane Database Syst Rev. 2004 Oct 18;(4):CD001747. doi: 10.1002/14651858.CD001747.pub2. Cochrane Database Syst Rev. 2004. PMID: 15495017 Updated. Review.
Confidence interval of treatment effect for the one trial recruiting patients with possible AD overlapped with the other six recruiting patients with probable AD. Galantamine's adverse effects appeared similar to those of other cholinesterase inhibitors and to be do …
Confidence interval of treatment effect for the one trial recruiting patients with possible AD overlapped with the other six recruiting pati …
Galantamine: a review of its use in Alzheimer's disease.
Scott LJ, Goa KL. Scott LJ, et al. Drugs. 2000 Nov;60(5):1095-122. doi: 10.2165/00003495-200060050-00008. Drugs. 2000. PMID: 11129124 Review.
Moreover, galantamine recipients achieved significantly better outcomes on behavioural symptoms than placebo recipients. ...Galantamine was generally well tolerated with the majority of adverse events being mild to moderate in intensity and transient. ...
Moreover, galantamine recipients achieved significantly better outcomes on behavioural symptoms than placebo recipients. ...Galant …
Galantamine attenuates autoinflammation in a mouse model of familial mediterranean fever.
Mughrabi IT, Ochani M, Tanovic M, Wang P, Diamond B, Sherry B, Pavlov VA, Ozen S, Kastner DL, Chae JJ, Al-Abed Y. Mughrabi IT, et al. Mol Med. 2022 Dec 9;28(1):148. doi: 10.1186/s10020-022-00571-9. Mol Med. 2022. PMID: 36494621 Free PMC article.
Multiple chronic disease markers were evaluated in animals that received long-term galantamine treatment compared to vehicle. RESULTS: Long-term treatment with galantamine attenuated the associated splenomegaly and anemia which are characteristic features of this di …
Multiple chronic disease markers were evaluated in animals that received long-term galantamine treatment compared to vehicle. RESULTS …
Galantamine for vascular cognitive impairment.
Craig D, Birks J. Craig D, et al. Cochrane Database Syst Rev. 2006 Jan 25;2006(1):CD004746. doi: 10.1002/14651858.CD004746.pub2. Cochrane Database Syst Rev. 2006. PMID: 16437493 Free PMC article. Updated. Review.
In the galantamine treated group, significantly higher numbers of patients dropped out and withdrew due to an adverse event. ...In both considered trials galantamine produced higher rates of gastrointestinal side-effects. ...
In the galantamine treated group, significantly higher numbers of patients dropped out and withdrew due to an adverse event. ...In bo …
Galantamine: additional benefits to patients with Alzheimer's disease.
Lilienfeld S, Parys W. Lilienfeld S, et al. Dement Geriatr Cogn Disord. 2000 Sep;11 Suppl 1:19-27. doi: 10.1159/000051228. Dement Geriatr Cogn Disord. 2000. PMID: 10971048 Review.
Cognitive and daily function were maintained throughout the 12 months in patients who received galantamine 24 mg/day. This sustained level of benefit may reflect galantamine's dual effect on the cholinergic system. Data from a 5-month, placebo-controlled stud …
Cognitive and daily function were maintained throughout the 12 months in patients who received galantamine 24 mg/day. This sustained …
Galantamine hydrobromide: an agent for Alzheimer's disease.
Zarotsky V, Sramek JJ, Cutler NR. Zarotsky V, et al. Am J Health Syst Pharm. 2003 Mar 1;60(5):446-52. doi: 10.1093/ajhp/60.5.446. Am J Health Syst Pharm. 2003. PMID: 12635450 Review.
The pharmacology, dosage, adverse effects, efficacy, and economics of galantamine hydrobromide are discussed. Galantamine hydrobromide is a tertiary alkaloid that has been extracted from plant sources and is now synthesized for use in the treatment of mild to modera …
The pharmacology, dosage, adverse effects, efficacy, and economics of galantamine hydrobromide are discussed. Galantamine hydr …
2,704 results

Searches related to "galantamine"